Spotlight on China Nat Med 12(3)
Nat Med 12(3) Mar 2006 published a series of news features about Chinese scholars.
Hongyuan Huang, Chaoyang Hospital, Beijing
He collect nasal cells, potentially neural stem cells, from aborted fetuses and injects them into people's spines. He clained his treament could be used for spinal cord injuries or diseases such as amyotrophic lateral sclerosis, Parkinson disease and multiple sclerosis. Despite the life quality improvement described by individual patients, the effects of his treamtent protocol needs to rule out placebo effect. Studies including good control groups are desired.
See also Nat news report.
Yongzhang Luo, Tsinghua University, Beijing
PhD from UC, Berkeley in 1993, Postdoc at harvard and standford from 1994-1998. He's been actively published on JBC, Biochemistry since his return in 1999. He is working on affordable medications for Chinese. Did I say drug discovery?
See more on his webiste at Tsinghua Univ.
See more on Nature news.
Hongkai Deng, Peking University, Beijing
PhD at UCLA, and postdoc at NYU. He won $1.9 million for a proposal to use stem cells to create mouse models for testing HIV and hepatitis C vaccines. Another project is to differenitate embryonic stem cell into insulin-secreting cell--Doug Melton has a new competitor in China. He also coauthored on the Chinese SARS paper on Nat 2006
Unfortunately, the Nat Med missed a star scholar in China, Xuetao Cao. Cao is a newly elected member of Chinese Academy of Engineering, and a professor of immunology at the Second Military Medical University, Shanghai and Zhejiang University at Hangzhou.
The government plans to increase its annual investment in research and development to 900 billion yuan (US$112 billion) by 2020, a massive increase over the current numbers
Hongyuan Huang, Chaoyang Hospital, Beijing
He collect nasal cells, potentially neural stem cells, from aborted fetuses and injects them into people's spines. He clained his treament could be used for spinal cord injuries or diseases such as amyotrophic lateral sclerosis, Parkinson disease and multiple sclerosis. Despite the life quality improvement described by individual patients, the effects of his treamtent protocol needs to rule out placebo effect. Studies including good control groups are desired.
See also Nat news report.
Yongzhang Luo, Tsinghua University, Beijing
PhD from UC, Berkeley in 1993, Postdoc at harvard and standford from 1994-1998. He's been actively published on JBC, Biochemistry since his return in 1999. He is working on affordable medications for Chinese. Did I say drug discovery?
See more on his webiste at Tsinghua Univ.
See more on Nature news.
Hongkai Deng, Peking University, Beijing
PhD at UCLA, and postdoc at NYU. He won $1.9 million for a proposal to use stem cells to create mouse models for testing HIV and hepatitis C vaccines. Another project is to differenitate embryonic stem cell into insulin-secreting cell--Doug Melton has a new competitor in China. He also coauthored on the Chinese SARS paper on Nat 2006
Unfortunately, the Nat Med missed a star scholar in China, Xuetao Cao. Cao is a newly elected member of Chinese Academy of Engineering, and a professor of immunology at the Second Military Medical University, Shanghai and Zhejiang University at Hangzhou.
posted by Zhang at 7:36 AM
0 Comments:
Post a Comment
<< Home